|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.930 USD | -18.21% |
|
-29.66% | -13.18% |
| 06-18 | TransCode Therapeutics, Inc. - Special Call | |
| 06-03 | TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a | MT |
| Market Cap | 5.64M 4.95M 4.6M 4.22M 7.94M 543M 8.06M 54.66M 21.35M 267M 21.15M 20.7M 922M | P/E 2024 |
-0.07x | P/E 2025 | -0.13x |
|---|---|---|---|---|---|
| Enterprise Value | -12.18M -10.7M -9.95M -9.13M -17.15M -1.17B -17.41M -118M -46.15M -577M -45.72M -44.73M -1.99B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
92.01% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: TransCode Therapeutics, Inc.
| 1 day | -18.21% | ||
| 1 week | -29.66% | ||
| Current month | -4.51% | ||
| 1 month | +21.14% | ||
| 3 months | -30.40% | ||
| 6 months | -39.92% | ||
| Current year | -13.18% |
| 1 week | 5.85 |  | 8.96 |
| 1 month | 4.57 | | 10.69 |
| Current year | 3.82 | | 12.6 |
| 1 year | 3.82 | | 20.99 |
| 3 years | 3.82 | | 118,271.9 |
| 5 years | 3.82 | | 1,000,000 |
| 10 years | 3.82 | | 1,000,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Calais
CEO | Chief Executive Officer | 67 | 2025-10-05 |
Zdravka Medarova
CTO | Chief Tech/Sci/R&D Officer | 52 | 2021-09-30 |
| Chief Executive Officer | 75 | 2024-01-12 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2018-06-30 | |
Philippe Calais
CHM | Chairman | 67 | 2021-02-17 |
Erik Manting
BRD | Director/Board Member | 54 | 2020-12-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/14/24 | Free | Director | 70,000 | 1.0654% | ||
| 6/14/24 | Free | Chief Executive Officer | 70,000 | 1.0654% | ||
| 6/14/24 | Free | Chief Financial Officer | 650,000 | 9.8934% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -18.21% | -29.66% | -46.09% | -99.99% | 5.64M | |
| +0.93% | +6.97% | +62.83% | +67.97% | 57.28B | |
| -1.92% | +6.03% | +43.68% | +84.56% | 54.99B | |
| -0.46% | -1.29% | +3.28% | +422.58% | 23.18B | |
| -2.97% | -2.35% | -22.03% | -16.54% | 22.59B | |
| -0.36% | +5.73% | +30.99% | -3.58% | 20.46B | |
| -1.34% | +0.51% | +25.02% | -30.27% | 17.56B | |
| -1.44% | +5.67% | +32.54% | +544.11% | 15.67B | |
| -1.30% | -5.02% | +165.62% | +291.37% | 14.46B | |
| -0.50% | -0.98% | +23.62% | +178.38% | 13.92B | |
| Average | -2.76% | -1.82% | +31.95% | +143.86% | 24.01B | |
| Weighted average by Cap. | -0.87% | +2.09% | +41.18% | +135.68% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -16.75M -14.72M -13.69M -12.56M -23.6M -1.61B -23.96M -163M -63.49M -793M -62.9M -61.54M -2.74B | -34.66M -30.44M -28.31M -25.98M -48.81M -3.34B -49.57M -336M -131M -1.64B -130M -127M -5.67B |
| Net Debt | -5.77M -5.07M -4.72M -4.33M -8.13M -556M -8.26M -55.99M -21.88M -273M -21.67M -21.2M -945M | -17.81M -15.65M -14.55M -13.35M -25.09M -1.72B -25.47M -173M -67.5M -843M -66.87M -65.43M -2.92B |
Employees
12
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-24 | US$5.930 | -18.21% | 24,561 |
| 26-07-23 | US$7.250 | -13.69% | 13,829 |
| 26-07-21 | US$8.400 | -3.78% | 10,822 |
| 26-07-20 | US$8.730 | +3.56% | 14,400 |
| 26-07-17 | US$8.430 | +1.93% | 5,860 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- RNAZ Stock
Select your edition
All financial news and data tailored to specific country editions
